If there’s one piece of pharma news that should come as no surprise, it’s FDA throwing a new drug back at its maker with a “Try again later.” After all, the agency spent last year handing out “approvable” letters like pharma hands out freebies. That’s why we’re surprised that analysts, reporters, and possibly […]

[Read more →]

The New York Times likes to give the drug industry a hard time with its (unbranded) scandal of the week series—off-label promoting, suppressing data, that sort of thing. But when the 2008 Pulitzer Prizes were handed out on Monday, the winner for best investigative reporting was a series by the Times that even its harshest […]

[Read more →]

Less than 24 hours after skewering CEO Jeffrey Kindler (right) in the press following Pfizer’s dismal Analyst Day, Wall Street’s large-cap analysts have done a stunning turnaround. In a rare show of remorse at their pitiless pile-on, these freshly contrite gurus of the pharma sector have declared the next five business days “Be Kinder to […]

[Read more →]

A morning-after assessment of the proof of concept news reveals that while Alnylam CEO John Maraganore (below) thinks he’s on a “moonwalk,” it’s really just cloud nine reached by “nice, small steps.”
Alnylam Pharmaceuticals’ announcement last Friday that it had scored the industry’s first human proof of concept with RNA interference sure sounded like a big […]

[Read more →]